On Monday, Shares of Comcast Corporation (NASDAQ:CMCSA), lost -1.10% to $57.76.
Comcast Corporation, declared it has named Michael J. Cavanagh Senior Executive Vice President and Chief Financial Officer of the company. He will join Comcast early this summer from The Carlyle Group, a global alternative asset manager, where he served as its Co-President and Co-Chief Operating Officer in New York. Preceding to Carlyle, Mr. Cavanagh spent almost 10 years as a member of the Operating Committee of JPMorgan Chase & Co. and served nearly six years as its CFO. He will be based at Comcast’s headquarters in Philadelphia.
Comcast’s appointment of Mr. Cavanagh follows a national search for a CFO after the company declared it reached a contract with Vice Chairman and current CFO Michael J. Angelakis to establish a new, planned company that will focus on investing in and operating growth-oriented companies, both domestically and internationally.
Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments. The Cable Communications segment offers video, high-speed Internet, and voice services to residential and business customers under the XFINITY brand name.
Shares of Union Pacific Corporation (NYSE:UNP), declined -0.64% to $106.75, during its last trading session.
Union Pacific Corporation, declared the sale of 111 acres in Fremont, California to Lennar Homes of California, Inc. The Company will recognize a pre-tax gain of about $110 million in the second quarter of 2015 as a result of this transaction. Lennar intends to utilize the property for transit-oriented development, counting a mix of residential, office, retail, industrial, research and development, school, and park uses. The sale parcel is the largest property in Fremont’s new Warm Springs “innovation district” and is adjacent to BART’s new passenger station, planned to open in the fall of 2015.
Union Pacific Corporation, through its partner, Union Pacific Railroad Company, operates railroads in the United States. The company offers freight transportation services for agricultural products, counting grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals compriseing of industrial chemicals, plastics, crude oil, liquid petroleum gases, fertilizers, soda ash, sodium products, and phosphorus rock and sulfur products.
At the end of Monday’s trade, Shares of Hecla Mining Co. (NYSE:HL), gained 2.67% to $3.08.
Hecla Mining Company, President and CEO, Phillips S. Baker, Jr., will take part in a panel talk aboution at the Bank of America Merrill Lynch Global Mining and Metals Conference in Barcelona, Spain, on Wednesday, May 13, 2015.
Jim Sabala, Sr. Vice President – CFO, will present at the Morgan Stanley Leveraged Finance Conference in New Orleans, on Wednesday, June 3, 2015, at 1:45 p.m. (CT).
Hecla Mining Company, together with its auxiliaries, discovers, acquires, develops, produces, and markets precious and base metal deposits worldwide. The company offers unrefined gold and silver bullion bars to precious metals traders; and lead, zinc, and bulk concentrates to custom smelters and brokers.
Finally, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), ended its last trade with -1.47% loss, and closed at $10.75.
ZIOPHARM Oncology, declared the appointment of Laurence J. N. Cooper, M.D., Ph.D., to the role of Chief Executive Officer, effective right away. Dr. Cooper brings extensive experience in pioneering the development of adoptive cellular therapies in the field of oncology and translating immunology into clinical practice. He succeeds Jonathan Lewis, M.D., Ph.D., who will remain a member of the Company’s Board of Directors.
Dr. Cooper joined The University of Texas MD Anderson Cancer Center in 2006, where his appointments comprise tenured professor, Pediatrics and Immunology; Section Chief, Cell Therapy, Children’s Cancer Hospital; and Associate Director, Center for Cancer Immunology Research. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle. Dr. Cooper has received numerous awards and honors and in addition to numerous other professional appointments, he has authored more than 140 journal articles, book chapters, and abstracts.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
